ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: ONO Pharmaceutical Co. Ltd is conducting a Phase I study titled ‘An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).’ The study aims to evaluate the safety and tolerability of ONO-4685, a promising treatment for these challenging conditions.
Intervention/Treatment: The study tests ONO-4685, an experimental drug administered via IV infusion. It is designed to continue until disease progression or unacceptable toxicity occurs, targeting relapsed or refractory T Cell Lymphoma and CLL/SLL.
Study Design: This is an open-label, single-group, Phase I interventional study with no masking. The primary purpose is treatment-focused, aiming to assess the drug’s safety and tolerability in a controlled setting.
Study Timeline: The study began on August 1, 2024, with the latest update submitted on June 1, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The ongoing recruitment and updates on this study could influence ONO Pharmaceutical’s stock performance, as successful outcomes may enhance investor confidence. The study’s progress is particularly relevant in the competitive oncology market, where advancements can significantly impact market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.